



Health innovation that matters

NEWS RELEASE

---

## LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results

**London, January 4, 2024** — LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2023 results prior to the call.

A live audiocast will be accessible at [www.livanova.com/events](http://www.livanova.com/events). Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 206069. A replay will be available on the LivaNova website for 90 days following the call.

### About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit [www.livanova.com](http://www.livanova.com).

### Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the next Company conference call. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

**LivaNova Investor Relations and Media Contacts**

+1 281-895-2382

**Briana Gotlin**

Director, Investor Relations

[InvestorRelations@livanova.com](mailto:InvestorRelations@livanova.com)

**Deanna Wilke**

VP, Corporate Communications

[Corporate.Communications@livanova.com](mailto:Corporate.Communications@livanova.com)

###